Inhibition of O-GlcNAcylation Decreases the Cytotoxic Function of Natural Killer Cells.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 22 12 2021
accepted: 14 03 2022
entrez: 28 4 2022
pubmed: 29 4 2022
medline: 30 4 2022
Statut: epublish

Résumé

Natural killer (NK) cells mediate killing of malignant and virus-infected cells, a property that is explored as a cell therapy approach in the clinic. Various cell intrinsic and extrinsic factors affect NK cell cytotoxic function, and an improved understanding of the mechanism regulating NK cell function is necessary to accomplish better success with NK cell therapeutics. Here, we explored the role of O-GlcNAcylation, a previously unexplored molecular mechanism regulating NK cell function. O-GlcNAcylation is a post-translational modification mediated by O-GlcNAc transferase (OGT) that adds the monosaccharide N-acetylglucosamine to serine and threonine residues on intracellular proteins and O-GlcNAcase (OGA) that removes the sugar. We found that stimulation of NK cells with the cytokines interleukin-2 (IL-2) and IL-15 results in enhanced O-GlcNAcylation of several cellular proteins. Chemical inhibition of O-GlcNAcylation using OSMI-1 was associated with a decreased expression of NK cell receptors (NKG2D, NKG2A, NKp44), cytokines [tumor necrosis factor (TNF)-α, interferon (IFN-γ)], granulysin, soluble Fas ligand, perforin, and granzyme B in NK cells. Importantly, inhibition of O-GlcNAcylation inhibited NK cell cytotoxicity against cancer cells. However, increases in O-GlcNAcylation following OGA inhibition using an OGA inhibitor or shRNA-mediated suppression did not alter NK cell cytotoxicity. Finally, we found that NK cells pretreated with OSMI-1 to inhibit O-GlcNAcylation showed compromised cytotoxic activity against tumor cells

Identifiants

pubmed: 35479087
doi: 10.3389/fimmu.2022.841299
pmc: PMC9036377
doi:

Substances chimiques

Cytokines 0
Serine 452VLY9402
Acetylglucosamine V956696549

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

841299

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI116730
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI144264
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007250
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA043703
Pays : United States

Informations de copyright

Copyright © 2022 Feinberg, Ramakrishnan, Wong, Asthana and Parameswaran.

Déclaration de conflit d'intérêts

RP is a consultant for Luminary Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Am J Physiol Heart Circ Physiol. 2012 May 15;302(10):H2122-30
pubmed: 22408028
Nat Immunol. 2008 May;9(5):477-80
pubmed: 18425103
Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17345-50
pubmed: 18988733
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):
pubmed: 33419956
Nat Commun. 2016 May 25;7:11686
pubmed: 27221592
Oncotarget. 2015 May 20;6(14):12529-42
pubmed: 25915426
ACS Chem Biol. 2015 Jun 19;10(6):1392-7
pubmed: 25751766
BMC Cancer. 2018 Nov 20;18(1):1141
pubmed: 30453909
Nat Commun. 2019 Jan 21;10(1):354
pubmed: 30664665
Blood. 2001 Jan 1;97(1):192-7
pubmed: 11133760
J Clin Invest. 1996 Jun 15;97(12):2722-7
pubmed: 8675682
J Bioenerg Biomembr. 2018 Jun;50(3):223-229
pubmed: 29404877
Cell Rep. 2021 Jan 5;34(1):108579
pubmed: 33406421
J Biol Chem. 2014 Dec 12;289(50):34472-81
pubmed: 25336656
Nat Commun. 2016 Apr 04;7:11154
pubmed: 27040177
Annu Rev Nutr. 2013;33:205-29
pubmed: 23642195
J Biol Chem. 1984 Mar 10;259(5):3308-17
pubmed: 6421821
EMBO J. 2007 Oct 17;26(20):4368-79
pubmed: 17882263
Front Endocrinol (Lausanne). 2018 Oct 16;9:595
pubmed: 30386294
J Biomed Sci. 2020 Apr 29;27(1):57
pubmed: 32349769
J Biol Chem. 2017 Jun 2;292(22):9150-9163
pubmed: 28416608
Cancer Res. 2006 Jan 1;66(1):517-26
pubmed: 16397268
Nature. 1976 Jun 24;261(5562):702-5
pubmed: 934318
Biochim Biophys Acta. 2010 Feb;1800(2):67-79
pubmed: 19732809
Mol Ther Methods Clin Dev. 2021 Jan 20;20:559-571
pubmed: 33665226
Front Immunol. 2021 Apr 29;12:652786
pubmed: 33995369
Front Cell Dev Biol. 2021 Oct 15;9:751761
pubmed: 34722537
J Immunol. 2016 Oct 15;197(8):3086-3098
pubmed: 27655845
Front Endocrinol (Lausanne). 2014 Nov 11;5:193
pubmed: 25426101
Front Oncol. 2014 Jun 03;4:132
pubmed: 24918087
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Front Immunol. 2020 Aug 28;11:1989
pubmed: 32983138
J Biol Chem. 2014 Dec 12;289(50):34457-65
pubmed: 25336642
Front Immunol. 2019 May 07;10:909
pubmed: 31134055
Int Immunol. 2006 Apr;18(4):505-13
pubmed: 16481345
Genes Dev. 2010 Dec 15;24(24):2784-99
pubmed: 21106670
J Exp Med. 1995 Sep 1;182(3):801-10
pubmed: 7650486
Glycobiology. 2021 Aug 7;31(7):812-826
pubmed: 33442719
Cell Res. 2004 Apr;14(2):155-60
pubmed: 15115617
Immunology. 2009 Sep;128(1):7-15
pubmed: 19689731
Nat Rev Cancer. 2011 Aug 18;11(9):678-84
pubmed: 21850036
Sci Signal. 2013 Aug 27;6(290):ra75
pubmed: 23982206
PLoS One. 2012;7(1):e29672
pubmed: 22238634
Nat Commun. 2018 Jun 14;9(1):2341
pubmed: 29904050
Blood. 2010 Mar 18;115(11):2167-76
pubmed: 19965656
Front Endocrinol (Lausanne). 2021 Apr 27;12:596617
pubmed: 33986724
Clin Cancer Res. 2015 Nov 15;21(22):5047-56
pubmed: 26567364
J Exp Med. 2015 Aug 24;212(9):1345-60
pubmed: 26261266
Annu Rev Biochem. 2011;80:825-58
pubmed: 21391816
Cell Immunol. 2018 Nov;333:85-92
pubmed: 29887419
Biologics. 2012;6:73-82
pubmed: 22532775
Cell Immunol. 2007 Jan;245(1):1-6
pubmed: 17481598
Immunol Rev. 1997 Feb;155:145-54
pubmed: 9059890
Immunity. 2019 Apr 16;50(4):1115
pubmed: 30995496

Auteurs

Daniel Feinberg (D)

Department of Pathology, Case Western Reserve University, Cleveland, OH, United States.

Parameswaran Ramakrishnan (P)

Department of Pathology, Case Western Reserve University, Cleveland, OH, United States.
Department of Biochemistry, Case Western Reserve University, Cleveland, OH, United States.
The Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.

Derek P Wong (DP)

Department of Pathology, Case Western Reserve University, Cleveland, OH, United States.

Abhishek Asthana (A)

Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH, United States.

Reshmi Parameswaran (R)

The Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH